Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版)No.25

Cancer Topics Index 05/06/2016(Daily Test version/ 日刊テスト版) No.25

Flags 【海外:overseas】
17 studies found for: cancer | received from 04/22/2016 to 04/22/2016

1 Recruiting
Fusion Guided Focal Laser Ablation of Prostate Cancer
Conditions: Prostate Cancer; Prostate Neoplasms
Intervention: Device: 1.2.Laser Ablation Device
Sponsor:National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:NCT02759744

2 Not yet recruiting
Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care
Conditions: Neoplasms; HIV; Healthcare Disparity
Intervention: Other: Potlako intervention
Sponsor:Harvard School of Public Health
ClinicalTrials.gov Identifier:NCT02752061

3 Not yet recruiting
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Condition: Urinary Bladder Neoplasms
Intervention: Procedure: Cryoablation
Sponsor:Huashan Hospital
ClinicalTrials.gov Identifier:NCT02760953

4 Not yet recruiting
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Anetumab ravtansine (BAY94-9343); Drug: Pegylated Liposomal Doxorubicin
ClinicalTrials.gov Identifier:NCT02751918

5 Not yet recruiting
Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
Condition: Breast Cancer
Intervention: Procedure: Axillary Lymph Node Sampling Clip
Sponsor:Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:NCT02752009

6 Not yet recruiting
A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Conventional radiotherapy; Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy
Sponsor:Lawson Health Research Institute
ClinicalTrials.gov Identifier:NCT02752126

7 Recruiting
Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy
Condition: Breast Cancer
Interventions: Behavioral: qualitative interviews with patients; Behavioral: questionnaires
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02753673

8 Not yet recruiting
A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers
Condition: Malignant Solid Tumor
Interventions: Biological: BMS-986179; Biological: Nivolumab
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02754141

9 Completed
Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer
Condition: Breast Cancer
Interventions: Behavioral: Prospective Surveillance Group; Behavioral: Education Group
Sponsor:University of British Columbia
ClinicalTrials.gov Identifier:NCT02754427

10 Completed
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Condition: Brain Neoplasm
Intervention: Biological: Gliolan
Sponsor:medac GmbH
ClinicalTrials.gov Identifier:NCT02755142

11 Not yet recruiting
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Microgynon; Drug: Nintedanib
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751385

12 Not yet recruiting
Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas
Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC)
Interventions: Drug: Birinapant; Drug: Paclitaxel; Drug: Carboplatin
Sponsor:Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:NCT02756130

13 Recruiting
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Condition: Cancer
Intervention: Drug: ARGX-110
Sponsor:arGEN-X BVBA
ClinicalTrials.gov Identifier:NCT02759250

14 Not yet recruiting
Real World Data on Gi(l)Otrif® Dose Adjustment
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gi(l)otrif®
Sponsor:Boehringer Ingelheim
ClinicalTrials.gov Identifier:NCT02751879

15 Recruiting
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Procedure: Haploidentical Stem Cell Transplantation
Sponsor:Leonardo Javier Arcuri
ClinicalTrials.gov Identifier:NCT02759822

16 Not yet recruiting
A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions: Drug: ASP2215; Drug: Azacitidine
Sponsor:Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier:NCT02752035

17 Not yet recruiting
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat; Drug: pembrolizumab + placebo
Sponsor:Incyte Corporation
ClinicalTrials.gov Identifier:NCT02752074

◇EU, EMA, CHMP, Cancer Research UK, NICE◇
A JOURNEY THROUGH CANCER (05/05/2016 Cancer Research UK)
Everyone’s journey through cancer is different.Here we try to portray the experience through the words of those who know it best.This article has been drawn together from the memories, reflections and stories that patients have shared with us.By sharing these stories, we hope to show a little of what it can be like to go through cancer.

<Medical Journal & Other News>
【黒色腫/免疫チェックポイント療法の応答を予測できるタンパク質 Bim】JOURNAL:JCI Insight
Protein may predict response to immunotherapy in patients with metastatic melanoma (05/05/2016 EurekAlert!/MAYO CLINIC)
ROCHESTER, Minn. -- A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight."Immune checkpoint therapy with PD-1 blockade has emerged as an effective treatment for many advanced cancers," says the study's lead author, Roxana Dronca, M.D., an oncologist at Mayo Clinic. "However, only a fraction of patients achieve durable responses to immunotherapy and, to date, we have had no means of predicting which patients are most likely to benefit."

【肺がん/4つのPD-L1アッセイの分析】2016 Annual Meeting of the American Association for Cancer Research (AACR)
Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released (05/05/2016 EurekAlert!/INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER)
DENVER - A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in non-small cell lung cancer (NSCLC) clinical trials.

【神経障害性疼痛を低減】JOURNAL:Cell Reports
Research findings reveal potential to reverse cancer-related nerve pain (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.The study in rats showed transfer of a gene known as KCC2 into the spinal canal restored chloride levels gone awry after nerve injury. Results from the research at The University of Texas MD Anderson Cancer Center, were published in the May 5 online issue of Cell Reports.

【卵巣がん/治療標的 miR551b】JOURNAL:Cell Reports
Study points to therapeutic target for common and aggressive ovarian cancer (05/05/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.The study results, published in the May 5 online issue of Cell Reports, were reported by a team led by Gordon Mills, Ph.D., chair of Systems Biology at The University of Texas MD Anderson Cancer Center.

Study Suggests Medical Errors Now Third Leading Cause of Death in the U.S. (May 3, 2016  The Johns Hopkins University)
医療ミス、米国で死因3位 研究 (05/05/2016 AFPBB:日本語)
Analyzing medical death rate data over an eight-year period, Johns Hopkins patient safety experts have calculated that more than 250,000 deaths per year are due to medical error in the U.S. Their figure, published May 3 in The BMJ, surpasses the U.S. Centers for Disease Control and Prevention’s (CDC’s) third leading cause of death — respiratory disease, which kills close to 150,000 people per year.The Johns Hopkins team says the CDC’s way of collecting national health statistics fails to classify medical errors separately on the death certificate. The researchers are advocating for updated criteria for classifying deaths on death certificates.

Graphics 【日本国内:Japan】
<Press Release:日本国内>
抗がん剤の副作用 免疫力の低下や味覚障害など (05/06/2016 NEWSポストセブン)

横浜市 がん患者に生活支援 かつら購入など一部助成 (05/05/2016 タウンニュース)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆先見経済 (2016年5月号)/清話会/発売日:2016年5月5日/価格(税込):3,240円
・進化し続けるガン治療最前線 筑間晃比古